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ABSTRACT PolyQ peptides teeter between polyproline II (PPII) and b-sheet conformations. In tandem polyQ-polyP peptides,
the polyP segment tips the balance toward PPII, increasing the threshold number of Gln residues needed for ﬁbrillation. To inves-
tigate the mechanism of cis-inhibition by ﬂanking polyP segments on polyQ ﬁbrillation, we examined short polyQ, polyP, and
tandem polyQ-polyP peptides. These polyQ peptides have only three glutamines and cannot form b-sheet ﬁbrils. We demon-
strate that polyQ-polyP peptides form small, soluble oligomers at high concentrations (as shown by size exclusion chromatog-
raphy and diffusion coefﬁcient measurements) with PPII structure (as shown by circular dichroism spectroscopy and 3JHN-Ca
constants of Gln residues from constant time correlation spectroscopy NMR). Nuclear Overhauser effect spectroscopy and
molecular modeling suggest that self-association of these peptides occurs as a result of both hydrophobic and steric effects.
Pro side chains present three methylenes to solvent, favoring self-association of polyP through the hydrophobic effect. Gln
side chains, with two methylene groups, can adopt a conformation similar to that of Pro side chains, also permitting self-
association through the hydrophobic effect. Furthermore, steric clashes between Gln and Pro side chains to the C-terminal
side of the polyQ segment favor adoption of the PPII-like structure in the polyQ segment. The conformational adaptability of
the polyQ segment permits the cis-inhibitory effect of polyP segments on ﬁbrillation by the polyQ segments in proteins such
as huntingtin.
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Genetic expansion of polyglutamine (polyQ) tracts is respon-
sible for Huntington’s disease and several other lethal neuro-
degenerative diseases (1). Other than the polyQ tract, there is
no homology among the proteins encoded by the affected
genes. The exact nature of the toxic species is still debated,
but it may be a protein aggregate (soluble or insoluble). It
is also possible that a ‘‘toxic’’ conformation of the monomer
of the expanded polyQ region is the cause of neuronal cell
death in all of these diseases (2–8).
Recent data from x-ray crystallography and solid-state
NMR suggest that polyQ and other Gln-rich peptides form
parallel, in-register b-sheet fibrils (9–14). Little is known,
however, about the structure of fibril precursors, such as
soluble oligomers and monomers of these peptides (15,16).
PolyQ aggregation differs from that of other fibril-forming
peptides in that in polyQ b-sheets, hydrogen bonds can
form between both main-chain and side-chain amide atoms
(14,17,18). This is in contrast to b-sheet forming peptides
such as b-amyloids, in which stacking of b-sheets involves
interactions predominantly among hydrophobic side chains
(19–21).
One notable feature of polyQ expansion diseases is that
there is a threshold in the number of Gln residues necessary
to cause disease. For Huntington’s disease, expansion of the
polyQ tract beyond 35–40 residues is invariably associated
with disease and protein deposits in cells, and longer polyQ
tracts are associated with earlier onset and more severe
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0006-3495/09/10/2295/11 $2.00disease (22). This threshold has been reproduced in models
such as Caenorhabditis elegans (23), Drosophila mela-
nogaster (24), Saccharomyces cerevisiae (25), mice (26),
and zebrafish (27), as well as in nonhuman primates (28).
The threshold number, however, is context-dependent (29).
In contrast to Huntington’s disease, the threshold for the spi-
nocerebellar ataxia (SCA) type 6 is only 20–30 residues (30).
The threshold for simpler synthetic peptides to form fibrils is
even shorter, as peptides with only six glutamines can form
insoluble b-sheets (31). Thus, the protein context and espe-
cially the sequences directly neighboring the polyQ tracts
affect the ability of these peptides to aggregate (32,33). In
huntingtin, a polyproline (polyP) tract flanks the polyQ
tracts, and this polyP tract acts as a cis-inhibitor of polyQ
aggregation (31,34).
Here, we investigate the structural basis of the mechanism
by which the polyP tract inhibits polyQ aggregation. We
present evidence that polyQ, polyP, and polyQ-polyP
peptides adopt a type of polyproline II (PPII) helical struc-
ture in solution, in agreement with previous studies by our
group (31) and others (35). In this work, we focus on a series
of short peptides with a polyQ tract or tandem polyQ-polyP
tracts in which the polyQ tracts are too short to form fibrils.
We previously showed that polyQ peptides with 3–15 Gln
residues teeter between a PPII-like and b-sheet structure,
and the presence of an adjacent polyP tract tips the balance
of tandem polyQ-polyP peptides toward the PPII conforma-
tion (31). This change in the ensemble of structures is asso-
ciated with an increase in the threshold length of the polyQ
segment needed for b-sheet fibril formation compared with
polyQ peptides without an adjacent polyP segment. Using
doi: 10.1016/j.bpj.2009.07.062
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(CD) spectroscopy, and size exclusion chromatography, we
demonstrate that a polyP segment does not act directly as a
‘‘folding nucleus’’ to induce a similar structure in adjacent
polyQ residues. Rather, the effect of the polyP segment on
an adjacent polyQ segment results from a combination of
factors, including the hydrophobicity and conformational
propensities of the covalently constrained Pro residues,
which permit self-association into small oligomers at high
concentrations. These oligomers have a PPII-like structure,
and we show, using constant time correlation spectroscopy
(CT-COSY) NMR and other experiments, that the Gln resi-
dues in such oligomers themselves adopt a PPII-like struc-
ture. Furthermore, steric clashes between Gln side chains
and Pro side chains to the C-terminal side of the polyQ
segment favor adoption of the PPII-like structure in the
polyQ segment. Thus, the effect of the polyP segment on
the adjacent polyQ segment is an indirect one that results
from a particular type of self-association of the hydrophobic
and conformationally constrained polyP segment into oligo-
mers with PPII structure. Finally, we will also present a
model for some of the intermediates in polyQ aggregation,
which includes soluble oligomers of polyQ-polyP peptides
with PPII-like structure, and in which the polyQ segments
permit aggregation in solution through hydrophobic contacts
among side-chain atoms.
MATERIALS AND METHODS
Peptide design and rationale
In this work, we utilize eight peptides with polyQ, polyP, or tandem polyQ-
polyP segments modeled on the N-terminal sequence of human huntingtin
protein. They can be grouped into two categories, based on sequences
flanking the polyQ and/or polyP segments, as follows:
Group I
R3GQ3GY
R3GQ3P11GY
R3GP11GY
R3AQ3AY
Group II
YAQ3AR
YAQ3P11AR
YAP11AR
YGQ3GR
In all glutamine-containing peptides, the polyQ segment is only three Gln
residues long, which precludes the formation of fibrils as occurs with longer
polyQ peptides. In addition, this length yields peptides in which the Gln resi-
dues have distinctive chemical shifts in NMR spectroscopy. The polyP tract
contains 11 Pro residues, which is the same as the polyP tract immediately
flanking the C-terminus of the polyQ tract in huntingtin. Arg residues are
included to increase water solubility, and Tyr is included as a chromophore.
Each group has a control peptide in which the linker residue is varied, i.e., in
group I, R3AQ3AY is a control for the other peptides with Gly as the linker
residue, and in group II, YGQ3GR is a control for the other peptides with Ala
Biophysical Journal 97(8) 2295–2305as the linker residue. Peptide synthesis and purification were essentially as
described previously (31), and are discussed in more detail in the Supporting
Material.
Disaggregation procedure
Peptides underwent a disaggregation procedure to ensure complete solubili-
zation, even though the peptides appeared to dissolve completely in water
similarly to previous findings (36,37). Further specifics are given in the
Supporting Material.
CD spectroscopy
CD spectra were measured using an Aviv model 202 spectropolarimeter
(Lakewood, NJ) with a temperature-controlled cell holder. Data were cor-
rected for background from buffer scans, converted to mean residue elliptic-
ities, and then corrected for baseline deviation. For most measurements,
peptides were freshly disaggregated and dissolved to yield concentrated
stock solutions in buffer. The peptides were then diluted to concentrations
ranging from 50 mM to a few millimolars with 10 mM sodium phosphate,
pH 7.00 or 3.00.
Initial CD spectra were obtained within 1 h of dilution from the concen-
trated stock; additional spectra were measured at various times up to 1 month,
as described in the Results section and the Supporting Material. Spectra were
measured using a 0.1 cm quartz cell (Starna, Atascadero, CA). Signals were
collected from 260 to 190 nm at 4C and 25C with 0.5 nm step size, 1 nm
bandwidth, and 1 s averaging time. The spectra are the result of six averaged
scans per sample, and measurements were repeated on at least three replicate
samples.
The methods used to assess the stability of the CD spectra over time are
given in the Supporting Material. As described in the Results section, all
peptides showed positive ellipticity atz215–230 nm, which was interpreted
as being consistent with PPII helix conformation (34,36,38). This positive
ellipticity decreased with increasing temperature, and this change was
completely reversible. The experimental procedures used to measure thermal
melting of peptides, and thermodynamically analyze that melting, are given
in the Supporting Material.
NMR spectroscopy
Experiments were performed using a Varian 600 MHz NMR spectrometer
(Palo Alto, CA) equipped with a triple resonance probe. Two-dimensional
1H spectra were performed to obtain residue-specific information on four
peptides (R3GQ3GY, R3GQ3P11GY, YAQ3AR, and YAQ3P11AR). Total
correlation spectroscopy (TOCSY) experiments were performed at ~0C,
25C, and 50C to assign resonances of each residue. Experiments were per-
formed at multiple temperatures because chemical shifts of all residues
changed with large changes in temperature, and this information was neces-
sary for the melting experiments described below. The acquisition time was
set to 0.5 s, and the mixing time was 0.06 s. Suppression of water signal was
achieved using eight presaturation pulses; generally, better suppression of
water signals was achieved at 5C than at 0C.
CT-COSY spectra were measured for the same four peptides to obtain
3JHN-Ha coupling constants at temperatures of 0–40
C, or in some cases,
up to 60C in 5C increments. Measurements were performed twice at all
temperatures—once on heating and once on recooling. For some peptides,
the spectral line shapes at temperatures above 40C became very broad at
pH 7.0. Preliminary experiments showed that this broadening was due in
part to rapid proton exchange of amide protons, and could be reduced by
lowering the pH to 5.0 or 1.5–3.0 (see Fig. 4). 3JHN-Ha coupling constants
were obtained and used to calculate torsional (f) angles, as described previ-
ously (39,40) and in the Supporting Material. Values obtained for the
f-angles indicate that a 3JHN-Ha coupling constant of 3–4 Hz is most consis-
tent with an a-helix, and a 3JHN-Ha coupling constant > 8 Hz suggests a
b-sheet (39). As described by Shi and Kallenbach, a 3JHN-Ha coupling
constant of 5–7 Hz is consistent with a PPII-like helical structure (40).
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for two peptides (R3GQ3GY and R3GQ3P11GY) at pH 7.0 (200 mM sodium
phosphate) and ~0C and 5C. The peptide concentrations were 3.80 and
2.68 mM for R3GQ3GY and R3GQ3P11GY, respectively. Spectra were
measured with mixing times of 80 and 300 ms for R3GQ3GY, and 75 and
200 ms for R3GQ3P11GY. Better signal/noise ratios were achieved at the
longer mixing times. The acquisition time was 250 ms, and the spectra are
reported below. TOCSY experiments were also performed on the same
samples and under the same conditions, except that the mixing time was
65 ms.
As an additional way to examine the aggregation state of polyQ and
polyQ-polyP peptides, we estimated the diffusion coefficients of two
peptides (R3GQ3GY and R3GQ3P11GY) using pulsed field gradient NMR,
and compared the effective hydrodynamic radii of these peptides in solution
with that of a protein standard, FN3s (a gift from Akiko Koide and Shohei
Koide, both from the University of Chicago, Chicago, IL). FN3s, a synthetic
construct for the 10th fibronectin type III domain, is a well-characterized,
compact, spheroidal, globular protein with a molecular weight of 9939.23
(41). The method used was essentially that of Jones et al. (42), which is
an application of an NMR method previously described by Gibbs and
Johnson (43). As discussed further in the Supporting Material, the signal
intensity in a pulse-gradient stimulated-echo longitudinal encode-decode
sequence causes spin-lattice relaxation to appear as an exponential decay
(44) in units proportional to time; thus, we obtain
I ¼ I0 expð ktÞ; (1)
where k ¼ rate constant, which is proportional to the diffusion constant, D.
The goal of these experiments was to compare the diffusion of our peptides
with that of a reference standard, using the following relationship:
RH; peptide ¼ Dstandard
Dpeptide
 RH; standard ¼ kstandard
kpeptide
 RH; standard;
(2)
where RH, peptide and RH, standard are the effective hydrodynamic radii, by the
Einstein-Stokes relationship, of the peptides and the reference standard,
respectively.
The goal of these experiments was to compare the hydrodynamic behavior
of FN3s, a protein of known dimensions, with that of R3GQ3GY and
R3GQ3P11GY. NMR and x-ray crystallographic studies (44–46) indicate
that fibronectin type III domains, including FN3s, are prolate ellipsoids,
with dimensions of ~43 A˚ 19 A˚ 17 A˚. From these dimensions, we can esti-
mate the effective spherical radius, RE, from the relationship RE ¼ (abc)1/3,
where a is the major axis, and b and c are the two minor axes, from which
we calculate RE for FN3s ~ 24.0 A˚. Since this number does not take into
account the hydration of the protein, the radius of gyration, Rg, may be some-
what larger. Although the structures of R3GQ3GY and R3GQ3P11GY are not
known, we considered two possible theoretical values for RG, calculated from
the following relationships:
R2g ¼
1
5

L
2
2
þ 2R2

(3)
for a symmetrical prolate ellipsoid, where R ¼ radius and L ¼ length, and
L <<< R; and
R2g ¼
R2
2
þ L
2
12
(4)
for cylindrical rods (47).
Size exclusion chromatography
Size exclusion chromatography of previously disaggregated peptides dis-
solved in 200 mM sodium phosphate, pH 7.00, was performed with theuse of Superdex 75 or Superdex Peptide columns. Further details of these
experiments are given in the Supporting Material.
RESULTS
CD spectra of short polyQ, polyP,
and polyQ-polyP peptides
In agreement with earlier results (31,34,38,48), the CD spectra
of freshly dissolved solutions of polyQ, polyP, and polyQ-
polyP peptides show a positive peak with lmax ~ 222–230 nm,
indicative of PPII or PPII-like structure (49,50). CD spectra of
other polyQ, polyP, and polyQ-polyP, and variants of those
peptides (group II) are shown in Fig. S1 and Fig. S2; CD
spectra of the above eight peptides (groups I and II) at
pH 3.0 are shown in Fig. S3. As shown in Fig. S4, these
patterns were stable over time, as the CD spectra did not
change significantly over the course of a month of incubation.
To examine the temperature dependence of the CD spectra
of these peptides (i.e., their thermal ‘‘unfolding’’), peptide
solutions were heated and cooled in increments of 5C, the
CD spectra were recorded, and the results were compared
with a null hypothesis, according to which there is a two-
state system (see Eq. S1, Eq. S2, Eq. S3, and Eq. S4). All
peptides showed completely reversible melting (Fig. 1 and
Fig. S5 show data for pH 7.00), as demonstrated by the
fact that the melting and cooling curves were essentially
superimposable. Fig. S6 and Fig. S7 show the observed ellip-
ticity at 229 nm, which is indicative of PPII-like helical
FIGURE 1 CD spectra showing thermal melting of polyQ, polyP, and
polyQ-polyP peptides. Panels A–D show CD spectra of R3GQ3GY,
R3GQ3P11GY, R3GP11GY, and R3AQ3AY, respectively, at temperatures
from 0 to 80C, at intervals of 5C, and in 10 mM sodium phosphate,
pH 7.00. For clarity, only the curves for heating of samples are shown;
the curves obtained from cooling samples are essentially superimposable
on those of the heating samples.
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II peptides, respectively. The maximal positive ellipticity for
R3GP11GY occurred at 229 nm. This spectrum was taken as
that of a bona fide PPII helical peptide, and therefore its
wavelength was used for all analyses. The fit of the data to
Eq. S4 shows only a slight curvature, indicative of noncoop-
erative melting (Fig. S6 and Fig. S7). The experimentally
accessible part of the curve was only a small portion of the
theoretical curve for unfolding, which approaches the
‘‘unfolded’’ state only at infinitely high temperatures.
Thus, the null hypothesis was incorrect, and the melting is
not indicative of a two-state system. Rather, this behavior
demonstrates local unfolding or unraveling of the PPII or
PPII-like helices, with loss of left-handedness, perhaps
toward a more extended structure.
These results, especially the noncooperative nature of the
thermal transition, underscore the difference between these
PPII-like helical peptides and many a-helical peptides.
Whereas the latter fold by forming folding nuclei, followed
by propagation of backbone hydrogen-bond arrays between
residues, no such cooperative folding or unfolding is
observed for the PPII and PPII-like peptides described here.
Fig. 2 shows the CD spectra of four peptides at various
concentrations and at 25C. Similar changes also occur at
4C (not shown). The mean residue ellipticity (MRE) changes
with concentration, as shown most clearly by the two peptides
containing polyP segments (R3GQ3P11GY and R3GP11GY;
FIGURE 2 Concentration dependency of the CD spectra of peptides.
Peptides were in 10 mM sodium phosphate, pH 7.00, and at 25C. (A)
R3GQ3GY at 73 (B), 95 (,), 241 (6), 500 (7), and 1000 (þ) mM. (B)
R3GQ3P11GY at 66 (B), 110 (,), 260 (6), 500 (7), and 1000 (þ) mM.
(C), R3GP11GY at 50 (B), 100 (,), 250 (6), 500 (7), and 1000 (þ)
mM. (D) R3AQ3AY at 50 (B), 100 (,), 250 (6), 500 (7), and 1000 (þ)
mM. PolyP-containing peptides show changes in spectra as concentration
is increased, suggesting self-association.
Biophysical Journal 97(8) 2295–2305Fig. 2, B and C), especially for the negative MRE values at
lower wavelengths. This pattern of change is consistent
with the notion that the polyP segments of these peptides
are constrained into a PPII helical structure even at low
concentrations, but increasing the concentration induces
structure in the less conformationally constrained portions
of the peptide, including the polyQ segment. A similar pattern
of changes in the far-ultraviolet region of the CD spectrum
has been observed for other polyQ-containing peptides
(34,35,51,52).
Size exclusion chromatography shows
oligomerization of polyQ peptides adopting
a PPII conformation
The above data demonstrate that polyQ peptides, with or
without a tandem polyP segment, adopt a PPII-like structure
at all concentrations tested; however, the data shown in
Fig. 2 suggest that a conformational change may occur with
increasing concentration, and that such a change may be
related to self-association. We used size exclusion chroma-
tography to determine whether oligomers were present. As
shown in Fig. 3, the polyQ-polyP peptides form small
FIGURE 3 Concentration dependency of the size exclusion chromato-
graphs of peptides. Peptides were eluted from the column in 200 mM sodium
phosphate, pH 7.00, and at room temperature (~22C), and were loaded onto
the Superdex Peptide column at various concentrations. (A) R3GQ3GY at
10 mM (orange), 60 mM (red), 100 mM (blue), 455 mM (green), 3.03 mM
(black), and 5.88 mM (cyan). The inset shows a magnified view of the region
of the chromatograph in which the oligomers elute. (B) R3GQ3P11GY at
10 mM (orange), 60 mM (red), 100 mM (blue), 455 mM (blue), and
2.75 mM (black). (C) R3GP11GY at 10 mM (orange), 45 mM (red),
100 mM (blue), 455 mM (green) and 2.25 mM (black). (D) R3AQ3AY at
10 mM (orange), 37 mM (red), 100 mM (blue), 455 mM (green), and
1.87 mM (black). Flow rate was 0.5 mL/min, void volume was at
15.4 min, and total volume was at 35.9 min.
Cis-Inhibition of PolyQ Fibrillation 2299oligomers at higher concentrations (as well as in high ionic
strength buffer, 200 mM sodium phosphate, pH 7.00) at
room temperature. In addition, R3GQ3GY also forms oligo-
mers, though only when higher (millimolar) concentrations
of peptide are loaded onto the column.
In size exclusion chromatography, peptides become
diluted as they migrate through the column; hence, the
peptide that is loaded onto the column is z10 times more
concentrated than when it emerges from the column. Thus,
while oligomer peaks are apparent in higher-concentration
samples (R100 mM), they are present at significantly lower
concentrations when the oligomers elute from the column.
Thus, we calculate from the extinction coefficient that
when 100 mM of R3GQ3P11GY are injected into the column,
the peak concentration of monomer eluting from the column
is ~15 mM.
TOCSY and CT-COSY NMR spectra
of oligomerizing polyQ and polyQ-polyP peptides
indicate PPII conformation over a range
of temperatures
To obtain residue-specific indicators of the conformations of
the Gln residues in the polyQ and polyQ-polyP peptides dis-
cussed above, we measured TOCSY and CT-COSY spectra
at a variety of temperatures from 0 to 60C and a pH range of
1.5–7.0. TOCSY spectra (see examples in Fig. S8) were
acquired at temperatures of 0C, 25C, and 50C to obtain
chemical shift information as a function of temperature, since
the location of the chemical shifts changes over this temper-
ature range.From the two-dimensional CT-COSY spectra, we ex-
tracted one-dimensional F2 traces at the Ha for each Q
residue. Such traces through the HN-Ha crosspeak appear as
antiphase doublets, with one positive and one negative
peak, separated by the HN-Ha coupling constant,
3JHN-Ha.
3JHN-Ha coupling constants were then used to compute back-
bone torsional (f) angles of these residues using a Karplus
relationship. The solvent had the same ionic strength as that
used for size exclusion chromatography, which indicated
peptide oligomerization, i.e., 200 mM sodium phosphate.
Peptide concentration was well into the millimolar range,
above the 455 mM concentration at which self-association
was observed by size exclusion chromatography and/or CD
spectroscopy. To obtain a more objective estimate of the
coupling constants, the curves from one-dimensional slices
of the spectrum were fitted to the equation of a difference of
two Lorentzian functions, as described in Materials and
Methods and in Eq. S5 (see the Supporting Material for
further details). Sample CT-COSY spectra and examples of
fits of the data to this equation are shown in Fig. S9 and
Fig. S10, respectively. As shown in Fig. 4, all three Gln
residues of both polyQ and polyQ-polyP peptides maintained
coupling constants that fell within a narrow range of z6–
8 Hz, at all temperatures tested from 0C to 60C and in the
pH range of 1.5–7.0. From the Karplus relationship (see
Materials and Methods and the Supporting Material), this
suggests values of fz 75–90, which is consistent with a
PPII helical conformation.
In addition, we examined TOCSY spectra of the Pro resi-
dues at multiple temperatures from 0 to 60C, and found
only minor variations of the chemical shifts of Cb, Cg,FIGURE 4 3JHN-Ha coupling constants for four peptides:
(A) R3GQ3GY, (B) R3GQ3P11GY, (C) YAQ3AR, and (D)
YAQ3P11AR. As described in Materials and Methods,
and Results, CT-COSY spectra were obtained for these
peptides at various temperatures. Because of the rapid
amide proton exchange at pH 7.0 and higher temperatures,
we also obtained data at lower pH values. Gln residues are
numbered as they occur in the amino acid sequence.
Symbols: , , and B for Gln1 at pH 7.0. 5.0, and
2.5–3.0, respectively; -, -, and , for Gln2 at pH 7.0.
5.0, and 2.5–3.0, respectively; and :, :, and 6 for Gln3
at pH 7.0. 5.0, and 2.5–3.0, respectively. Values with error
bars represent the mean 5 standard deviation of two
measurements at the same temperature.Biophysical Journal 97(8) 2295–2305
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ppm (data not shown). These chemical shifts are consistent
with a trans peptide bond (39), and suggest that the secondary
structure of the Pro residues does not change within this
temperature range.
Diffusion of R3GQ3GY and R3GQ3P11GY indicates
formation of soluble oligomers
As described in Materials and Methods, we used pulsed field
gradient NMR spectroscopy to compare the diffusion coef-
ficients of two peptides (R3GQ3GY and R3GQ3P11GY) with
that of a reference standard protein, FN3s, a synthetic fibro-
nectin type III domain (41). Fig. 5, A–C, show the decay of
signal intensity with time for the dominant (backbone
amide) peaks associated with these two peptides and
protein, respectively, with all of the signals normalized to
an initial value of one; the nonnormalized signal decays
are shown in Fig. S11. Fig. 5 D shows the t1/2 values calcu-
lated for decay of the signals from the amide proton peaks of
R3GQ3GY and R3GQ3P11GY, and for 20 representative
peaks from the FN3s. The mean value for the first-order
rate constant for the decay of T2 of R3GQ3GY,
R3GQ3P11GY, and FN3s were 7.6  105, 6.1  105,
and 5.2  105, respectively. Using a value of 24.0 A˚ for
the minimal hydrodynamic radius for FN3s, we calculate
RH ¼ 16.4 and 20.5 A˚ for R3GQ3GY and R3GQ3P11GY,
respectively.
Thus, the relative diffusion coefficients estimated for
R3GQ3GY and R3GQ3P11GY are larger than would be
expected for a monomer, which is consistent with the view
that both of these peptides form small oligomers in solution.
The observed values forRH are close to that of FN3s. Although
the shapes of the small oligomers of R3GQ3GY and
R3GQ3P11GY are not known, the monomers would have to
have an extremely high axial ratio to explain these high
numbers entirely in terms of asymmetry. To take an extreme
example, consider R3GQ3GY and R3GQ3P11GY depicted as
completely rigid, rod-shaped molecules with a PPII conforma-
tion. From molecular modeling of these peptides as PPII
helices (see Fig. 7), this corresponds to lengths of ~25.5 and
~56.7 A˚ for R3GQ3GY and R3GQ3P11GY, and a diameter
of ~7.6 A˚ for both peptides. Even given the extreme case of
a completely rigid rod, we calculate radii of gyration of 7.8
and 16.5 A˚, respectively. These values are both smaller than
the observed values for RH. Although the difference is not
definitive, the assumption of a completely rigid rod for polyP
peptides is an exaggeration, as previously shown experimen-
tally by fluorescence resonance energy transfer (FRET)
measurements (53–55) that revealed the flexibility of polyP
peptides. Thus, our data suggest that R3GQ3P11GY and
possibly even R3GQ3GY form small soluble oligomers,
with ~2–4 molecules per aggregate, and with the dominant
NMR signals coming from the aggregated species.
Biophysical Journal 97(8) 2295–2305FIGURE 5 Estimation of diffusion coefficients of R3GQ3GY and
R3GQ3P11GY by comparison with a protein standard, FN3s (42,43). Data
are shown for the backbone amides of two peptides ((A) R3GQ3GY and
(B) R3GQ3P11GY) and for (C) the protein standard FN3s, a small protein
of known dimensions. Points are experimental data; lines are fits to the equa-
tion of a monoexponential decay (Eq. 1). The figure also includes several
peaks derived from buffer instead of the peptides.
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peptides support a PPII-like helical conformation
and suggest modes of stabilization of the PPII-like
structure
NOESY spectra were obtained for R3GQ3GY and
R3GQ3P11GY at peptide concentrations of 3.80 and
2.68 mM, respectively, and for both in 200 mM sodium phos-
phate, pH 7.00, at 5C. At these concentrations of peptide and
salt, both peptides were shown (by CD spectroscopy,
size exclusion chromatography, and diffusion coefficient
measurements) to form soluble oligomers in which the
peptide assumed a PPII helical structure, and CT-COSY
spectra indicated that the Gln residues, in particular, were
among those that adopted the PPII helical structure. In the
NOESY experiments, of particular interest was the possibility
that NOEs can exist between either backbone NH or Ca
protons of the three Gln residues, and the Cb, Cg, or Nd
protons of the same residue.
Fig. 6 A shows the HN-Ca region of the NOESY spectrum
of R3GQ3GY (300 ms mixing time), and Fig. 6 C shows a
similar region of the spectrum of R3GQ3P11GY (200 ms
mixing time). Close-ups of the regions containing the Ca
and side-chain protons of the three Gln residues are shown
in Fig. 6, B and D, for R3GQ3GY and R3GQ3P11GY. Both
peptides show clear crosspeaks between the Ca protons and
the Cb and Cg protons of the same residue, and the intensities
of these crosspeaks increase with increasing mixing time.
These data indicate that the side chain of the Gln residues
FIGURE 6 NOESY spectra of R3GQ3GY (A and B), and R3GQ3P11GY
(C and D). R3GQ3GY concentration is 3.80 mM and R3GQ3P11GY concen-
tration is 2.68 mM, both samples in 200 mM sodium phosphate (with 0.1%
NaN3, w:v), pH 7.00, 5
C. A and C show the ‘‘footprint’’ (HN-Ha) region of
the NOESY spectra of these peptides. B and D highlight NOEs between Ca
protons of each of the three Gln residues and both Cb and Cg protons of the
same residue. Numbers in the figure refer to the residue numbers in the two
peptides.forms a compact structure, with all atoms in close proximity
to the peptide backbone, and the side chain oriented toward
the N-terminus of the peptide. These findings are anticipated
for a PPII-like helical structure with a ‘‘folded-back’’ side
chain, but not for an extended b-strand structure in which
the side chain would be more fully extended above and below
the peptide backbone, and the Cg protons would be too
distant from the backbone to show easily observable NOEs.
Our findings suggest that glutamines can adopt this
‘‘folded-over conformation’’, as previously seen in crystal
structures (56,57).
Molecular modeling of polyQ and polyQ-polyP
peptides suggests that the hydrophobic effect
mediates self-association of PPII helical peptides
As shown above, polyQ and polyQ-polyP peptides adopt
a stable PPII-like helical structure (Figs. 1, 2, and 4, and
Fig. S1, Fig. S2, and Fig. S3). Furthermore, in this conforma-
tion, these peptides may self-associate into small soluble
oligomers, as suggested by CD spectroscopy (Fig. 2), size
exclusion chromatography (Fig. 3), and diffusion coefficient
measurement (Fig. 5 and Fig. S11), all of which were per-
formed at fairly high ionic strengths to enhance the hydro-
phobic effect (58,59). Finally, NOESY NMR experiments
(Fig. 6) indicated that under conditions in which these
peptides formed oligomers, the Gln residues were part of
a PPII-like helix with side chains in a compact or ‘‘folded-
over’’ conformation. We used molecular modeling to inves-
tigate the mechanism by which polyQ and polyQ-polyP
peptides might self-associate when they form a PPII-like
helix.
Fig. 7 shows polyQ and polyQ-polyP peptides arrayed in
PPII helical conformations using f ¼ 75 and j ¼ 150.
The overall shape of these peptides, arrayed in this fashion,
FIGURE 7 PolyQ-polyP peptide (Q15P11) arrayed as a PPII helix
(f ¼ 75, j ¼ 150). (A) Close-up view showing the side chains of Gln
and Pro in similar conformations. (B and C) Full length of the peptide in
side view and end-on view, respectively, showing the PPII helical conforma-
tion with ‘‘folded-over’’ side chains.Biophysical Journal 97(8) 2295–2305
2302 Darnell et al.is rod-like. In this conformation, the peptides form a solvent-
exposed hydrophobic surface consisting of the entire side
chain of Pro residues, and the b- and g-methylene carbon
atoms of Gln residues. Yoon et al. (60) examined polyP
peptides and proposed that self-association of these peptides
could result from interactions between these hydrophobic
ridges. As shown in Fig. 7, a similar hydrophobic ridge can
also arise in polyQ peptides when they adopt a PPII-like
conformation and the side chains are ‘‘folded over’’ toward
the backbone. Thus, a polyQ segment appears prone to self-
associate through hydrophobic interactions when it adopts
a PPII-like helix with this compact side-chain structure that
resembles that of Pro side chains.
DISCUSSION
In this work, we have shown that short polyQ, polyP, and
polyQ-polyP tandem peptides adopt a stable PPII or PPII-
like structure in solution, and that soluble oligomers of these
peptides display that conformation. The polyP and polyQ-
polyP peptides that contained the relatively hydrophobic
polyP segment had a greater tendency to self-associate
than peptides that contained only polyQ segments. Self-asso-
ciation was demonstrated by the change in the pattern of the
CD spectrum (MRE) with peptide concentration, by size
exclusion chromatography, and by diffusion coefficient
measurements using pulsed field gradient NMR.
For all of the polyQ-containing peptides, the polyQ
segment was only three residues long, and thus too short to
form b-sheet fibrils. Especially in the context of an adjacent
polyP segment, the polyQ-containing peptides self-associated
as PPII-like helical peptides. As demonstrated in Fig. 7, polyP
peptides are constrained to present a hydrophobic edge,
formed by the methylene groups in their side chains, toward
the solvent (60), which favors self-association through the
hydrophobic effect. For simplicity, these models assume an
all-trans conformation in the polyP segment; however, as
shown by Eaton and co-workers (53,54), internal cis prolines
can introduce kinks into the chain, and are primarily respon-
sible for the higher than expected observed FRET efficiency
in polyP peptides. This caveat notwithstanding, the majority
of Pro residues have trans peptide bonds, as depicted in
Fig. 7 and evaluated by TOCSY experiments. Fig. 7 also
shows the Gln residues arrayed in a similar conformation,
with side-chain structures strikingly similar to those of the
Pro residues, i.e., with two methylene groups oriented toward
the solvent, and the side-chain amide in proximity to the
backbone, possibly also including the formation of a hydrogen
bond between side-chain and backbone amide atoms.
NOESY spectra (Fig. 6) demonstrate that our peptides do
indeed adopt a conformation of this type: the Gln side chains
form a compact structure close to the peptide backbone, with
the potential for hydrophobic self-association.
For disease-causing polyQ proteins, such as huntingtin,
genetic expansion of the polyQ tract beyond a sharp threshold
Biophysical Journal 97(8) 2295–2305is associated with disease, and longer polyQ tracts are
associated with more severe and earlier-onset disease. This
threshold, however, varies with the ‘‘context’’ (i.e., the
protein in which the polyQ occurs) (22,29,32,33). In hunting-
tin, polyQ domains of >35–40 residues lead to disease,
whereas 20–30 Gln residues in the a1A-voltage-dependent
calcium channel subunit lead to SCA type 6 (30). For short
polyQ peptides, the threshold for fibril formation is much
shorter: ~6 Gln residues (31). Presumably, the large globular
domains of huntingtin inhibit efficient packing of some of
the polyQ domain. In addition, huntingtin contains a polyP
domain adjacent to the polyQ domain, and the polyP domain
inhibits aggregation in vitro. Similarly, an adjacent polyP
domain inhibits fibril formation by synthetic polyQ peptides,
and increases the threshold from 6 to 9–12 Gln residues
(31,34). We previously showed that this effect occurs because
the polyP tract tends to induce a PPII-like conformation in the
adjacent polyQ tract. A polyQ tract can readily adopt either
a PPII-like or b-sheet conformation, and the polyP tract tips
the balance toward the PPII-like conformation (31). It is
also noteworthy that the polyP tract has this cis-inhibitory
effect on fibrillation only if it is placed to the C-terminal
side of the polyQ tract; the effect does not occur if it is placed
to the N-terminal side (34).
The results presented here can help to explain both the
threshold phenomenon and the requirement that the polyP
segment must be placed to the C-terminal side of the polyQ
tract. Indeed, it was perplexing that the polyP tract should
be able to ‘‘induce’’ a PPII-like conformation in an adjacent
polyQ tract at all, since the PPII-helix (and similar structures
formed by polyQ peptides) showed no cooperativity of
folding, in contrast to a-helices (61–63), where a nucleation
event initiated helix formation followed by cooperative
folding of the remainder of the helix. We observed completely
noncooperative thermal ‘‘unfolding’’ (see, for example, Fig. 1
and Fig. S5, Fig. S6, and Fig. S7), perhaps to a somewhat
more extended structure, of polyQ, polyP, and polyQ-polyP
peptides.
As shown in Fig. 7, the ‘‘induction’’ of a PPII-like structure
in the polyQ segment of polyQ-polyP peptides could be attrib-
utable in part to the self-association of the polyP segment
(47,60). In the setting of an oligomer, where one hydrophobic
edge of Pro residues associates with another, the Gln residues
could assume a conformation similar to that of the Pro resi-
dues. Since the Pro side chain is covalently constrained, the
Gln residues could follow suit and adopt a similar structure
only if the Gln side chains are oriented toward the N-terminus
of the peptide, as also depicted in Fig. 7.
Such self-association was apparent at high peptide concen-
trations. Even allowing for dilution of peptides as they
migrate through size exclusion chromatography columns,
the oligomer peak accounted for a small percentage of the
total peptide. It is unlikely, therefore, that self-association
through the hydrophobic effect alone accounts for cis-inhibi-
tion of polyQ aggregation by an adjacent polyP segment. In
Cis-Inhibition of PolyQ Fibrillation 2303addition to this effect, at least three other effects may account
for cis-inhibition.
First, as suggested by NMR and modeling, a Pro residue to
the C-terminal side of a Gln residue occludes much of the
conformational freedom of the Gln side chain, and thereby
favors folding of the Gln side chain into a compact structure
resembling the Pro side chain. Our results help to explain the
fact that polyP inhibits polyQ fibrillation only when the
polyP segment is to the C-terminal side of the polyQ segment
(34).
Second, the rod-like polyP segment may act as a rigid strut,
limiting the conformational freedom of the polyQ segment.
Since the polyQ segment itself has a high tendency to adopt a
PPII-like structure, it does so when conformationally con-
strained against adopting another structure, such as a b-sheet.
A third effect is suggested by our recent experiments on
side-chain N-methylated polyQ peptides, which act as trans-
inhibitors of polyQ aggregation (J. D. Lanning, unpublished
results). Although the affinity of inhibitors (e.g., one desig-
nated 5QMe2) for a fibril-forming target polyQ peptide,
YAQ12A, is only moderate (Kd ~ 1 mM), complexes form in
a chaperone-like manner, with very rapid binding and desorp-
tion of inhibitor and target. Thus, such inhibitors are active
even at significantly substoichiometric inhibitor concentra-
tions (e.g., 1:10 ¼ inhibitor/target). In a similar way, even
low concentrations of small oligomers of QnPm peptides
with a PPII-like structure could inhibit fibril formation. In
both cases (the N-methylated inhibitor and small oligomers
of QnPm peptides), inhibition of fibrillation may stem from
the fact that nucleation is slow and results from a rare confor-
mational change. Wetzel and co-workers have argued that the
nucleus for polyQ fibril formation could even be a monomer
of altered conformation (64). Thus, fibrillation and its
inhibition can be represented be the following scheme:
Complex
þ 5QMe2[Y 5QMe2
PPII-like QnPm
)
/ 
Nucleus
/ Fibril
[Y
PPII-like QnPm Oligomer:
Formation of the nucleus is unfavorable for both polyQ and
polyQ-polyP peptides, but apparently it is more so for the
latter. We infer from our observations that either the self-asso-
ciation of a polyQ-polyP peptide (depicted as QnPm in the
above scheme) into an oligomer with PPII-like structure, or
the formation of a complex with an inhibitor peptide such as
5QMe2, in effect ‘‘resets the clock’’. Upon dissociation, thepolyQ-polyP peptide is again a monomer with a PPII-like
structure, and the slow process of nucleation begins anew.
In addition to the P11 segment adjacent to the polyQ
domain of huntingtin, there are two additional Pro-rich
segments of similar length. The codons for Gln differ by
only one nucleotide from two of the codons for Pro. In
view of the tendency of polyQ domains to expand and lead
to protein aggregation diseases, it is possible that polyP
domains arose adjacent to the polyQ domains as a protection
against this tendency (65). An understanding of these effects
could help lead to the future development of reagents that
can affect the tendency of polyQ-containing proteins to
self-associate. Indeed, recently developed inhibitors have
been shown to act by forming a heterodimeric complex
that stabilizes the PPII-like state of polyQ peptides (J. D.
Lanning, unpublished results).
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